A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. [electronic resource]
Producer: 20150825Description: 11154-67 p. digitalISSN:- 1949-2553
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab
- Cohort Studies
- Dose-Response Relationship, Drug
- Female
- Humans
- Indoles -- administration & dosage
- Male
- Middle Aged
- Neoplasms -- drug therapy
- Niacinamide -- administration & dosage
- Oligonucleotides
- Recombinant Fusion Proteins -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.